Bayer/Algeta win 1st mCRPC alpha-emitting pharmaceutical OK
This article was originally published in Scrip
Executive Summary
With the speed at which Dr Richard Pazdur's office at the FDA is approving cancer drugs in recent months, one would think the Office of Hematology and Oncology Products was on steroids, or at least, drinking a lot of legal stimulant beverages.